28 results
Thumbnail

D3.230 - Type I Hypersensitivity Among Private Dental Practitioners: Clinical Manifestations and Associated Factors

Thumbnail

D3.221 - Cat Immunotherapy and Real-Life Data: A Single-Center Experience

Thumbnail

D3.220 - Real-World Management of Pediatric Allergic Diseases: A Nationwide Physician Survey among Allergists and Pediatric Allergists in Turkey

Thumbnail

D3.215 - Shifting patterns of mite sensitization in Southern Europe: Real-World diagnostic and immunotherapy practices in Spain and Portugal (MITE-WISE Project)

Thumbnail

D3.216 - Determination of Allergenic Activity of Native Mugwort Allergen Preparations by a Competitive IgE-Binding Test

Thumbnail

D3.217 - Development and validation of a monoclonal antibody-based competitive ELISA to accurate quantification of Blo t 2 in native Blomia tropicalis allergenic extracts

Thumbnail

D3.218 - When the sting is not the sensitizer: a vespid venom allergy case

Thumbnail

D3.222 - Monitoring the immune response during the first year of SCIT in Ragweed allergy

Thumbnail

D3.223 - Crossroads of Venom and Bite: A case of Horsefly - Wasp Cross - reactive Anaphylaxis

Thumbnail

D3.225 - Two years Sublingual SQ-Grass Pollen Tablet Immunotherapy Combined with Dupilumab Induces Longterm Suppression of Immediate Cutaneous Allergen Sensitivity

Thumbnail

D3.226 - Prophylactic sublingual peanut immunotherapy alters antibody responses and downstream allergen reactivity in a Brown Norway rat model

Thumbnail

D3.227 - The effect of subcutaneous allergen immunotherapy after one year on the quality of life of children with perennial allergic rhinitis and rhinoconjunctivitis

Thumbnail

D3.228 - One-Year Changes in Molecular sIgE Profiles During House Dust Mite Immunotherapy: A Pilot Study

Thumbnail

D3.229 - Comparison of mold sensitization profiles in children (2021 and 2025): impact of environmental deterioration during martial law

Thumbnail

D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma

Thumbnail

D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report

Thumbnail

D1.108 - Optimization of phenotyping in severe T2-bronchial asthma

Thumbnail

D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy

Thumbnail

D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients

Thumbnail

D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study